606
Participants
Start Date
November 30, 2008
Primary Completion Date
September 30, 2013
Study Completion Date
December 31, 2013
Aflunov (Single prime, single boost)
Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
Aflunov (Single prime, single boost)
Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
Aflunov (single prime, single boost)
Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Aflunov (single prime, single boost)
Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Aflunov (Double prime, single boost)
Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
Aflunov (double prime, single boost)
Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
Aflunov (double prime, single boost)
Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Aflunov (double prime, single boost)
Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
Aflunov (No prime, single boost)
No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
University Hospitals Leicester, Leicester
Clincal Trials Unit Leicester Royal Infirmary, Leicester
Collaborators (2)
Medical Research Council
OTHER_GOV
Novartis
INDUSTRY
Public Health England
OTHER_GOV
National Institute of Biological Standards and Control
OTHER_GOV
University Hospitals, Leicester
OTHER